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Melatonin rescues cardiovascular dysfunction during hypoxic
development in the chick embryo
Abstract: There is a search for rescue therapy against fetal origins of
cardiovascular disease in pregnancy complicated by chronic fetal hypoxia,
particularly following clinical diagnosis of fetal growth restriction (FGR).
Melatonin protects the placenta in adverse pregnancy; however, whether
melatonin protects the fetal heart and vasculature in hypoxic pregnancy
independent of effects on the placenta is unknown. Whether melatonin can
rescue fetal cardiovascular dysfunction when treatment commences following
FGR diagnosis is also unknown. We isolated the effects of melatonin on the
developing cardiovascular system of the chick embryo during hypoxic
incubation. We tested the hypothesis that melatonin directly protects the fetal
cardiovascular system in adverse development and that it can rescue
dysfunction following FGR diagnosis. Chick embryos were incubated under
normoxia or hypoxia (14% O2) from day 1  melatonin treatment (1 mg/kg/
day) from day 13 of incubation (term ~21 days). Melatonin in hypoxic chick
embryos rescued cardiac systolic dysfunction, impaired cardiac contractility
and relaxability, increased cardiac sympathetic dominance, and endothelial
dysfunction in peripheral circulations. The mechanisms involved included
reduced oxidative stress, enhanced antioxidant capacity and restored vascular
endothelial growth factor expression, and NO bioavailability. Melatonin
treatment of the chick embryo starting at day 13 of incubation, equivalent to
ca. 25 wk of gestation in human pregnancy, rescues early origins of
cardiovascular dysfunction during hypoxic development. Melatonin may be a
suitable antioxidant candidate for translation to human therapy to protect the
fetal cardiovascular system in adverse pregnancy.
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Introduction
In addition to the interaction between genetic makeup and
traditional lifestyles risk factors, such as smoking, obesity,
or a sedentary life, it is now established that a component
of heart disease-risk can be predetermined by adverse con-
ditions before birth during early development [1, 2]. A
common consequence of adverse pregnancy is chronic fetal
hypoxia, and several independent studies in humans and
animal models have reported that chronic fetal hypoxia
can trigger a fetal origin of cardiac dysfunction and
increase the risk of cardiovascular disease in later life [3–
10]. Therefore, there is accumulating interest in establish-
ing the mechanisms underlying this association to identify
potential therapeutic strategies for intervention.
Previously, our laboratory raised the hypothesis that
oxidative stress may be a candidate mechanism linking
chronic fetal hypoxia, a fetal origin of cardiovascular dys-
function and programming of cardiovascular disease in the
adult offspring [8]. Chronic fetal hypoxia promotes oxida-
tive stress in the fetal cardiovascular system [4, 5, 8, 9] and
maternal treatment with the antioxidant vitamin C in
hypoxic pregnancy prevented the programming of cardio-
vascular dysfunction in the adult offspring [8]. Although
the latter study provided proof of principle to support the
hypothesis tested, only high doses of vitamin C incompati-
ble with human treatment were effective to act as an antiox-
idant in vivo. Further, both maternal treatment with
vitamin C and fetal hypoxia started concurrently in early
gestation. In human clinical practice, intrauterine growth
restriction (IUGR) as a result of chronic fetal hypoxia may
be only reliably diagnosed at around 25 wk of gestation.
Therefore, there is interest in identifying alternative transla-
tional antioxidant therapy in tolerable doses that may res-
cue cardiovascular dysfunction triggered by chronic fetal
hypoxia once diagnosis has been feasible.
An alternative candidate therapeutic agent is melatonin.
Melatonin is a powerful antioxidant that increases nitric
oxide (NO) bioavailability because of its combined ability
to directly scavenge free radicals, to enhance endogenous
antioxidant enzyme capacity and to reduce the leakage of
electrons from the mitochondrial electron transport chain
through improving its function. In addition, the metabo-
lites of melatonin also possess antioxidant properties. Such
antioxidant roles of melatonin have been comprehensively
and extensively reviewed in recent reports [11, 12]. Further,
melatonin treatment protects placental perfusion, fetal
growth, and fetal cardiovascular function in pregnancy
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complicated by chronic adverse intrauterine conditions
[13–15]. Consequently, a human clinical trial testing the
efficacy to protect fetal growth of maternal oral melatonin
administration in complicated pregnancy has recently
been launched [16]. However, whether the antioxidant
actions of melatonin protect the developing fetal heart
and circulation directly, independent of its protective
effects on the placenta and umbilical perfusion in adverse
pregnancy is completely unknown.
The chick embryo is the only animal model that permits
isolation of the effects of hypoxia and of antioxidant ther-
apy on fetal growth and on the developing cardiovascular
system independent of effects on the placental and/or
maternal physiology [17–20]. Therefore, in this study, we
have tested the hypothesis that melatonin has direct pro-
tective effects on the fetal heart as well as the fetal vascula-
ture in adverse development. Adopting an integrative
approach at the isolated organ, cellular, and molecular
levels, we investigated the effects of melatonin treatment in
chick embryos incubated under normoxic or hypoxic con-
ditions from day 1 of development on cardiac function,
peripheral vascular reactivity, cardiac stereology and vas-
cular morphology, and on cardiac molecular indices of
oxidative stress, antioxidant capacity, and of NO bioavail-
ability. Treatment of chick embryos with melatonin
started at day 13 of incubation, which is equivalent to ca.
25 wk of gestation in human pregnancy.
Methods
Animals
All procedures were performed under the UK Animals
(Scientific Procedures) Act 1986 and were approved by the
Ethical Review Committee of the University of Cam-
bridge. Fertilized Bovans Brown eggs (Medeggs, Norfolk,
UK) were weighed and incubated under normoxic (21%
O2) or hypoxic (14  0.5% O2) conditions (37.9°C, 45%
humidity, 12:12 hr light:dark cycle, automatic rotation
every hour, Masalles incubator Mod-75A, equipped with
electronic servo-controlled humidity cool steam injection
system HS-Auto-3.5L; Masalles, Barcelona, Spain) from
day 1. The levels of oxygen, humidity, and temperature
inside the incubators were continuously monitored
(DD103 DrDAQ Oxygen Sensor, Pico Technology, St.
Neots, UK). Chick embryos were treated with melatonin
(1 mg/kg/day, Sigma-Aldrich, Dorset, UK) or vehicle
(100 lL water for injection, Norbrook Laboratories,
Corby, UK) from day 13 to day 18 of incubation. Mela-
tonin was injected daily into the air cell onto the chorioal-
lantoic membrane via a 1-mm hole in the eggshell. The
hole was covered with sticky tape at all other times. All
treatment procedures were performed under sterile condi-
tions. The dose of melatonin was extrapolated from exper-
iments in our laboratory, which showed successful
antioxidant effects in rodent pregnancy [13].
Analysis of hematocrit and growth
On day 19, embryos underwent euthanasia by cervical
spinal transaction and their body weight was recorded.
Blood was collected in micro-hematocrit tubes (Vitrex,
Modulohm, Denmark) directly from the heart in dupli-
cate, and the hematocrit was determined. The heart and
brain were dissected and weighed. The heart was snap fro-
zen in liquid nitrogen and stored at 80°C until molecular
analysis.
Molecular analysis of oxidative stress, antioxidant
defences, and vascular endothelial growth factor
(VEGF) in the embryo heart
The expression of 3-nitrotyrosine (3-NT), 4-hydroxynone-
nal (4-HNE) and superoxide dismutase (SOD), the activity
of catalase, and the levels of total nitrate and nitrite
(NOx) in the 19-day chick embryo heart were determined
by commercial assay kits (3-NT: ab116691, Abcam, Cam-
bridge, UK, 4-HNE: E12H0203, AMS biotechnology,
Abington, UK, SOD: Sigma-Aldrich, Catalase: 707002;
Cayman Chemical Company, Ann Arbor, MI, USA,
NOx: 78001, Cayman Chemical Company).
The expression of glutathione peroxidase (GPx) and of
VEGF protein in the 19-day chick embryo heart was
determined by Western blot, as described [21]. Heart pro-
tein (10 lg) was loaded onto each lane, and Coomassie
blue staining was used as a loading control. GPx (anti-
GPx 1, Abcam) and VEGF (anti-VEGF, Abcam) primary
antibodies and HRP-conjugated anti-rabbit secondary
antibody were used. Proteins were detected using West
Pico Chemiluminescent substrate (Thermo Scientific,
Loughborough, UK). The membranes were visualized by
exposing them to a photosensitive film (GE Healthcare
Amersham Hyperfilm ECL, Fisher Scientific, Loughbor-
ough, UK). The intensities of the bands were analyzed
with the AlphaEase imaging software (Alpha Innotech,
San Leandro, CA, USA).
Analysis of cardiac function using the Langendorff
preparation
In another group of embryos, the heart was rapidly
excised following cervical transection on day 19 of incuba-
tion. The heart was immediately placed in ice-cold Krebs–
Henseleit Buffer (KHB, NaCl:120 mM, KCl:4.7 mM,
MgSO2.7H2O:1.2 mM, KH2PO4:1.2 mM, NaHCO3:25 mM,
glucose:10 mM, CaCl2.2H2O:1.3 mM) and mounted onto
the apparatus. The heart was perfused through the coro-
nary arteries via the aorta with KHB (40°C, gassed with
95% O2 and 5% CO2) at a constant pressure (40 cm
H2O). A small incision was made in the left atrium, and a
small balloon was inserted into the left ventricle via the
atrium. The balloon was filled with distilled water using a
100-lL Hamilton syringe and attached to a rigid distilled
water-filled catheter connected to a calibrated pressure
transducer (Argon Medical Devices, Plano, TX, USA).
The balloon volume was adjusted to 30 lL to obtain a
value for left ventricular end diastolic pressure (LVEDP)
between 5 and 10 mmHg [8, 22, 23]. After the stabilization
period, baseline recordings were made for heart rate (HR),
LVEDP, and left ventricular systolic pressure (LVSP). Left
ventricular developed pressure (LVDP) was calculated by
subtracting LVEDP from LVSP. The maximum first
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derivative (dP/dtmax) and the minimum first derivative
(dP/dtmin) of the left ventricular pressure were calculated
using an IDEEQ data acquisition system (version 0-2.5.0,
Maastricht, Netherlands). Coronary flow rate (CFR) was
determined by timed collections of cardiac perfusate
effluent.
Changes in HR and LVDP in response to the sympa-
thetic b1 adrenoreceptor agonist isoprenaline (()-Isopro-
terenol (+)-bitartrate salt, Sigma-Aldrich, 109–107 M)
and to the parasympathetic muscarinic agonist carbachol
(carbamylcholine chloride, Sigma-Aldrich, 108–106M)
were measured. The HR and LVDP responses were
expressed as a percentage change from the baseline, and
then, the ratio of the maximal HR (chronotropic) and
LVDP (inotropic) responses to isoprenaline and to carba-
chol was calculated. A recovery time ranging between 5
and 15 min was allowed between each treatment bolus to
permit HR and LVDP to stabilize at baseline values
before the administration of the next bolus.
Cardiac stereology and morphology of the aorta
On day 19 of incubation, another group of embryos were
anaesthetized with sodium pentobarbital (0.1 mL i.p. Pen-
toject; Animalcare Ltd, York, UK). The heart was
exposed, an incision was made in the right atrium, and it
was perfusion fixed at a constant pressure of 2.66 kPa [24]
with 10% formaldehyde via a needle inserted into the left
ventricle. A segment of the fixed descending aorta at the
level of the cardiac apex and the fixed heart were stored in
formaldehyde for 24 hr and then in phosphate buffered
saline at 4°C until further analysis. The heart was sectioned
at 1 mm thickness with a heart slicer (Zivic Instruments,
Pittsburgh, PA, USA), and the sections were imaged on a
light box. Quantitative analysis of the heart was performed
using ImageJ (version 1.46, National Institute of Health,
Bethesda, MD, USA) by superimposing a point grid on
the cardiac sections. The volumes of the left ventricle (LV),
left lumen, right ventricle (RV), and right lumen were
quantified using the Cavalieri’s principle [25]. The seg-
ments of aorta were embedded in a paraffin block and then
sectioned at 5 lm thickness. Ten consecutive sections were
collected from the distal end and stained with hematoxylin
and eosin. Quantitative analysis was performed using the
Computer-Assisted Stereology Toolbox system (CAST ver-
sion2.0, Olympus, Albertslund, Denmark).
Analysis of peripheral vascular reactivity using wire
myography
A third-order branch of the left femoral artery was dis-
sected under a dissecting microscope (Stemi 2000; Zeiss,
Cambridge, UK) from the same embryos used for the
analysis of cardiac function via the Langendorff prepa-
ration at day 19 of incubation. Arterial segments
(2 mm) were threaded with two pieces of stainless steel
wire (40 lm diameter) and secured in a 4-chamber
microvascular myograph (Multi Wire Myograph System
610M; DMT, Aarhus, Denmark). The chamber con-
tained 5 mL of cold Kreb’s buffer (NaCl:118.5 mM,
KCl:4.75 mM, MgSO4.7H20:1.2 mM, KH2PO4:1.2 mM,
NaHCO3:25.0 mM, CaCl2:2.5 mM, glucose:5.55 mM,
gassed with 95% O2 and 5% CO2) and it was heated
slowly to 37°C. The segment was equilibrated for
20 min and then stretched until a physiological transmu-
ral pressure of 2.66 kPa was achieved (DMT normaliza-
tion module; DMT). Vasodilator response to cumulative
doses of sodium nitroprusside (SNP, 1010–104 M) and
of acetylcholine (ACh, 109–105 M) was assessed after
preconstricting the vessel with a suboptimal dose of
potassium (K+, <85% of maximal response to K+
125 mM). The partial contributions of endogenous NO-
dependent and NO-independent mechanisms to the
vasorelaxation were determined by repeating the ACh
dose–response curve after incubating the vessel with L-
NAME (105 M, 10 min). Vascular constrictor capacity
was assessed with increasing doses of K+ solutions
(16.74–250 mM) and of phenylephrine (PE, 108–
104 M). The response to K+ was normalized to the
diameter of the vessel (mN/mm/lm/1000). The response
to phenylephrine was normalized to the response to
125 mM K+ of the same vessel (%K+125).
LabChart was used for data acquisition and analysis
(Labchart 6.0, Powerlab 8/30; AD Instruments, Chal-
grove, UK).
Analysis of circulating melatonin concentration
To estimate the likely diurnal concentration of circulating
melatonin concentration achieved in the chick embryo
during daily dosing with melatonin, another nine groups
of normoxic chick embryos (n = 3–6 per group) and
another nine groups of hypoxic chick embryos (n = 3–6
per group) were administered 1 mg/kg on day 18–19 of
incubation as before and blood was collected at 0, 0.5, 1,
2, 3, 4, 6, 8, or 24 hr following treatment. The embryos
were killed by cervical transection, and blood was col-
lected directly from the heart into dipotassium EDTA
tubes (Teklab, Durham, UK) and centrifuged for 5 min at
2370 rcf. Supernatant was stored at –80°C until analysis.
The plasma melatonin concentration was determined using
a commercial ELISA kit (CSB-E08132h, CUSABIO,
Wuhan, China). The detection range of the assay was
3.13–800 pg/mL. The intra-assay coefficient of variation
(CV) was <8%, and the interassay CV was <10%.
Statistical analysis
All data are expressed as mean  S.E.M. Statistical com-
parisons were made using one- or two-way ANOVA with
the Tukey or Bonferroni post hoc test, as appropriate. For
all comparisons, statistical significance was accepted when
P < 0.05 (Graphpad prism version 5.00, Graphpad Soft-
ware, Inc. San Diego, CA, USA).
Results
In normoxic embryos, plasma melatonin concentrations
peaked at 124  78 pg/mL between 0.5 and 1 hr following
treatment, after which melatonin decreased progressively
toward basal levels (Fig. 1). In contrast, in hypoxic
embryos, although plasma melatonin concentrations
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peaked at similar concentrations (127  61 pg/mL), this
elevation occurred at 2 hr following treatment, after which
melatonin decreased more irregularly toward basal levels
(Fig. 1). However, there was no difference in the total cir-
culating concentration of melatonin achieved within the
24-hr day in normoxic (517  253, n = 36) or hypoxic
(402  176 pg/mL, n = 39) embryos.
Relative to normoxic embryos, embryos incubated
under hypoxic conditions showed significantly elevated
hematocrit, reduced absolute body weight, or body weight
expressed relative to the initial egg mass, an enhanced
brain-to-body weight ratio and decreased absolute heart
weight in proportion to the reduced body weight
(Fig. 2A–F). Melatonin treatment in hypoxic embryos did
not affect the enhanced hematocrit, reduced body weight,
or increased brain-to-body weight ratio; however, the
absolute heart weight was no longer significantly different
from normoxic embryos (Fig. 2A–F). Melatonin treatment
in normoxic embryos did not affect any of these variables
(Fig. 2A–F).
Relative to normoxic embryos, hearts of embryos incu-
bated under hypoxic conditions showed significantly
enhanced expression of 3-NT and 4-HNE but significantly
decreased levels of combined nitrate and nitrite concentra-
tions. Hearts of embryos incubated under hypoxic condi-
tions also showed a significantly reduced expression of
SOD and significantly impaired catalase activity but no
change in GPx protein expression (Fig. 3D–F). Melatonin
treatment in hypoxic embryos prevented the increase in
cardiac 3-NT and 4-HNE levels and restored cardiac NOx
levels (Fig. 3A–C). Melatonin treatment in hypoxic
embryos also augmented the cardiac catalase activity, and
it significantly enhanced the cardiac GPx expression but it
did not affect the impaired cardiac expression of SOD
(Fig. 3D–F). Melatonin treatment in normoxic embryos
also led to a significant increase in the cardiac GPx expres-
sion (Fig. 3F). Relative to normoxic embryos, hearts of
embryos incubated under hypoxic conditions showed sig-
nificantly enhanced expression of VEGF (Fig. 4). Mela-
tonin treatment in hypoxic embryos restored the cardiac
Fig. 1. Plasma melatonin concentration
in normoxic and hypoxic chick embryos
with or without melatonin treatment.
Values are mean  S.E.M. of plasma
melatonin levels in day 19 chick embryos
incubated in normoxia or hypoxia before
(0 min) or after (0.5, 1, 2, 3, 4, 6, 8, or
24 hr) a bolus dose of melatonin (5 lg).
Groups are normoxia (N, white
histogram, n = 36) and hypoxia (H,
black histogram, n = 39). Significant
(P < 0.05) differences are as follows:
* versus 0 hr of the corresponding group
(Two-way ANOVA with Bonferroni post
hoc test).
Fig. 2. Hematocrit and fetal biometry in normoxic and hypoxic chick embryos with or without melatonin treatment at day 19 of incuba-
tion. Values are mean  S.E.M. at day 19 of hematocrit (A), absolute embryo weight (B), relative embryo weight (C), brain weight rela-
tive to body weight (D), heart weight (E), and heart weight relative to body weight (F) of chick embryos incubated in either normoxia (N,
n = 10), hypoxia (H, n = 10), hypoxia with melatonin (HM, n = 11), or normoxia with melatonin (NM, n = 10). Significant (P < 0.05)
differences are as follows: * versus N (one- or two-way ANOVA with Tukey and Bonferroni post hoc test, respectively).
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VEGF expression to control values. Melatonin treatment
in normoxic embryos did not affect the cardiac expression
of VEGF (Fig. 4).
Relative to normoxic embryos, embryos incubated under
hypoxic conditions showed significantly impaired LVDP,
dP/dtmax, and dP/dtmin, but significantly elevated LVEDP
and an enhanced value for the ratio of the maximal HR
(chronotropic) and LVDP (inotropic) response to isopre-
naline and carbachol (Fig. 5A–F). Melatonin treatment in
hypoxic embryos restored LVDP, dP/dtmax, dP/dtmin, and
the ratios of the chronotropic and inotropic responses to
isoprenaline and carbachol. However, LVEDP remained
significantly elevated compared to normoxic embryos. In
addition, while hypoxic incubation alone did not affect
CFR, melatonin treatment in hypoxic embryos significantly
increased CFR relative to normoxic embryos (N:6.7  0.4,
H:9.3  0.9, HM:13.5  1.9*, NM:9.2  1.2 mL/min/g of
heart tissue, P < 0.05; * versus N). Melatonin treatment in
normoxic embryos did not affect cardiac function. The
ratio of the maximal LVDP and HR responses to isopre-
naline and carbachol was not different in normoxic
embryos with or without melatonin treatment (Fig. 5E,F).
Relative to normoxic embryos, embryos incubated under
hypoxic conditions showed significantly reduced values for
the wall volume and significantly increased values for the
lumen volume of the left ventricle without affecting these
values in the RV. Consequently, the ratio of the left ventric-
ular wall to lumen volume was markedly decreased in
hypoxic relative to normoxic embryos (Fig. 6A–J). The
increase in left ventricular lumen volume and the reduction
in the ratio of the left ventricular wall to lumen volume
were no longer significant between normoxic embryos and
hypoxic embryos treated with melatonin. However, mela-
tonin treatment in hypoxic embryos did not significantly
alter the reduced wall volume of the left ventricle (Fig. 6A–
J). Melatonin treatment in normoxic embryos did not affect
left or right ventricular morphology (Fig. 6A–J). Relative
to normoxic embryos, embryos incubated under hypoxic
conditions showed a reduced ratio of the wall to lumen area
of the aorta (Fig. 7D). Melatonin treatment in hypoxic
embryos increased the lumen area and decreased the wall
area of the aorta, such that the reduction in the wall to
lumen area of the aorta measured in hypoxic embryos was
not significantly affected (Fig. 7A–D). Melatonin treatment
Fig. 3. Indices of oxidative stress and antioxidant defences in hearts from normoxic or hypoxic chick embryos with or without melatonin
treatment at day 19 of incubation. Values are mean  S.E.M. at day 19 of the expression of 3-nitrotyrosine (A), the expression of
4-hydroxynonenal (B), total nitrate and nitrite concentration (C), the expression of superoxide dismutase (D), catalase activity (E), and
the expression of glutathione peroxidase (F) in the hearts of chick embryos incubated in either normoxia (N, n = 9), hypoxia (H, n = 10),
hypoxia with melatonin (HM, n = 10), or normoxia with melatonin (NM, n = 10). n = 6 for all groups for (F). Significant (P < 0.05) dif-
ferences are as follows: * versus N. † H versus HM (one- or two-way ANOVA with Tukey and Bonferroni post hoc test, respectively).
Fig. 4. Cardiac vascular endothelial growth factor (VEGF)
expression in hearts from normoxic or hypoxic chick embryos
with or without melatonin treatment at day 19 of incubation.
Values are mean  S.E.M. at day 19 of the heart VEGF expres-
sion in the chick embryo incubated in either normoxia (N, n = 6),
hypoxia (H, n = 6), hypoxia with melatonin (HM, n = 6), or nor-
moxia with melatonin (NM, n = 6). Significant (P < 0.05) differ-
ences are as follows: * versus N. † H versus HM (one- or two-way
ANOVA with Tukey and Bonferroni post hoc test, respectively).
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in normoxic embryos did not affect the whole cross-sec-
tional area of the aorta (Fig. 7A–D).
The femoral vasodilator response to SNP was not signifi-
cantly affected by hypoxic incubation or by treatment with
melatonin under normoxic or hypoxic conditions (Fig. 8A).
However, relative to normoxic embryos, embryos incubated
under hypoxic conditions showed significantly impaired
femoral vasodilator sensitivity to ACh, primarily by affect-
ing NO-independent mechanisms (Fig. 8B,C). Melatonin
treatment in hypoxic embryos restored the femoral dilator
response to control values by significantly enhancing both
NO-dependent and NO-independent mechanisms (Fig. 8B,
C). Melatonin treatment in normoxic embryos did not affect
the femoral dilator reactivity to ACh (Fig. 8B,C).
The femoral vasoconstrictor responses to potassium and
to phenylephrine were also tested. Relative to normoxic
embryos, embryos incubated under hypoxic conditions had a
significantly enhanced maximal constrictor response to
potassium, while the responses to phenylephrine were simi-
lar. Melatonin treatment in hypoxic embryos did not affect
the constrictor response to potassium, but it significantly
increased the constrictor response to phenylephrine. Mela-
tonin treatment in normoxic embryos did not affect the
femoral constrictor reactivity to potassium or to phenyle-
phrine (Potassium: N:2.0  0.3; H:3.9  0.7*;
HM:3.9  0.5*; NM:2.7  0.1 mN/mm/lm/1000. Phenyle-
phrine: N:116  5%; H:120  5%; HM:156  17%*;
NM:123  6% K+125 mM).
Discussion
The data in this study show that treatment of the chroni-
cally hypoxic chick embryo with melatonin from day 13
of incubation, equivalent to ca. 25 wk of gestation in
human pregnancy, rescues cardiac systolic dysfunction,
impaired cardiac contractility and relaxability, increased
cardiac sympathetic dominance, and endothelial dysfunc-
tion in peripheral circulations. The mechanisms mediating
the protective effects on the cardiovascular system of
melatonin in the chronically hypoxic chick embryo
include reduced oxidative stress, enhanced antioxidant
capacity and restored VEGF expression, and NO
bioavailability. Therefore, the data in this study support
the hypothesis tested that melatonin has direct protective
effects on the fetal heart as well as the fetal vasculature in
adverse development in addition to beneficial effects on
placental function. As antioxidant-induced protection in
the chronically hypoxic chick embryo occurred despite
administration after 13 days of hypoxic incubation, mela-
tonin may be a plausible candidate for translation to
human clinical therapy to rescue fetal cardiovascular dys-
function once fetal growth restriction (FGR) diagnosis
has been possible.
In the present study, hypoxic development in the chick
embryo increased hematocrit and cardiac VEGF expres-
sion, and it induced asymmetric growth restriction and
affected cardiac and peripheral vascular function with con-
sequences for the morphology of the heart and major ves-
sels, such as the aorta. Hypoxia induces the activation of
the hypoxia-inducible factor-1 (HIF-1), which binds to the
hypoxia response elements of the erythropoietin [26] and
vegf [27, 28] genes, enhancing their transcription. There-
fore, the data confirm that exposure of the chick embryo to
14% oxygenation from the beginning of incubation
induced established molecular and hematologic indices of
chronic fetal hypoxia.
Fig. 5. Cardiac function in normoxic or hypoxic chick embryos with or without melatonin treatment at day 19 of incubation. Values are
mean  S.E.M. at day 19 of the left ventricular developed pressure (LVDP, A), myocardial contractility (dP/dtmax, B), left ventricular
end diastolic pressure (C), myocardial relaxability (dP/dtmin, D), the ratio of the maximal heart rate responses to isoprenaline and to car-
bachol (chronotropic sympathetic dominance, E), and the ratio of the maximal LVDP response to isoprenaline and to carbachol (inotro-
pic sympathetic dominance, F) of chick embryos incubated in either normoxia (N, n = 10), hypoxia (H, n = 10), hypoxia with melatonin
(HM, n = 11), or normoxia with melatonin (NM, n = 10). Significant (P < 0.05) differences are as follows: * versus N. † H versus HM
(one- or two-way ANOVA with Tukey and Bonferroni post hoc test, respectively).
21
Melatonin and embryonic cardiovascular function
The effects of chronic hypoxia from the beginning of
incubation on the developing cardiovascular system are
consistent with those described by other studies in the
chick embryo and in other species. Several studies have
reported peripheral vascular dysfunction, myocardial wall
thinning, reduced myocardial contractility, and impaired
cardiac systolic function following early developmental
hypoxia in the rodent fetus and neonate, the chick
embryos, and in young children [29–31]. Sharma et al. [32]
reported dilated cardiomyopathy, a lower maximal ven-
tricular developed pressure with enhanced end-systolic vol-
ume and decreased ejection fraction, consistent with
impaired systolic function following chronic hypoxia in
the chick embryo. Gilbert [33] reported that myocardial
cell contractile function was impaired in the chronically
hypoxic ovine fetus. Under these conditions, cardiac sym-
pathetic dominance may be an adaptive response to main-
tain cardiac output. Accordingly, Lindgren and Altimiras
[34] reported that chronic hypoxia sensitizes beta-adrener-
gic receptors in the chick embryo heart. Of interest,
sustained increases in myocardial contractility due to
heightened sympathetic excitation have been strongly asso-
ciated with future cardiovascular dysfunction and eventual
heart failure in humans [35, 36]. Therefore, the present
study adds new conceptual insight into the literature,
reporting that similar cardiac and vascular dysfunction
triggered by early developmental hypoxia in the chick
embryo can be diminished by melatonin treatment.
In the present study, melatonin treatment prevented the
increased expression of molecular indices of oxidative
stress in the chick embryo heart, such as nitrotyrosine, a
footprint for peroxynitrite, and 4-hydroxy-2-nonenal, an
established marker of lipid peroxidation. Melatonin treat-
ment also restored hypoxia-induced decreases in the activ-
ity of the antioxidant catalase, and it increased the
expression of GPx in the chick embryo heart. Diminished
oxidant stress coupled with maintained or enhanced
antioxidant defences are mechanisms which likely explain
the capacity of melatonin treatment to restore cardiac NO
bioavailability. Therefore, findings in the present study are
Fig. 6. Cardiac stereology in normoxic or hypoxic chick embryos with or without melatonin treatment at day 19 of incubation. Values
are mean  S.E.M. at day 19 of the heart left ventricular (LV) wall volume (A), LV lumen volume (B), LV wall-to-lumen volume ratio
(C), right ventricular (RV) wall volume (D), RV lumen volume (E), and RV wall-to-lumen volume ratio (F) of chick embryos incubated
in either normoxia (N, n = 10), hypoxia (H, n = 10), hypoxia with melatonin (HM, n = 10), or normoxia with melatonin (NM, n = 10).
Representative mid-cardiac sections of day 19 chick embryos incubated in normoxia (G), hypoxia (H), hypoxia with melatonin (I), and
normoxia with melatonin (J). Scale bar: 1 mm. Significant (P < 0.05) differences are as follows: * versus N. (one- or two-way ANOVA
with Tukey and Bonferroni post hoc test, respectively).
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not only consistent with developmental hypoxia triggering
cardiovascular dysfunction secondary to oxidative stress
[8, 10, 37] and with the protective effects of melatonin on
the developing cardiovascular system being due to mela-
tonin having antioxidant actions [38–42], but they further
expand our understanding by showing that oxidative
stress-induced cardiac dysfunction triggered by develop-
mental hypoxia can be rescued by antioxidant treatment
starting much later than the onset of hypoxia. This is
important in terms of translation to the human clinical sit-
uation, when chronic fetal hypoxia leading to IUGR can
only be reliably diagnosed at around 25 wk of gestation.
We and others have reported that the antioxidant
actions of melatonin increase umbilical blood flow via
NO-dependent mechanisms and that the indole amine is
protective on placental function [14, 42–44]. Consequently,
maternal supplementation with melatonin in undernour-
ished pregnancy in rats increased birthweight [13]. Such
findings have led to the design and implementation of a
human clinical trial to test the therapeutic efficacy of
maternal oral melatonin administration in protecting FGR
[16]. The lack of a protective effect of melatonin on FGR
in the hypoxic chick in the present study is consistent with
the beneficial effects of melatonin on growth being at the
level of the placenta and therefore absent in avian species.
An elegant study by Tintu et al. [30] suggested that the
mechanism of adverse actions of developmental hypoxia
on the cardiovascular system included those mediated by
VEGF, as systemic administration of recombinant VEGF
during chick embryo development mimicked the hypoxia-
induced cardiac dilatation [30]. Interestingly, in vivo treat-
ment with sFlt-1, a soluble receptor and a scavenger of
(A)
(B) (D) (G) (H)
(C)
(E) (F)
Fig. 7. Aortic morphology in normoxic or hypoxic chick embryos with or without melatonin treatment at day 19 of incubation. Values
are mean  S.E.M. at day 19 of the total vessel area (A), wall area (B), lumen area (C), and wall-to-lumen area ratio (D) of the aorta of
chick embryos incubated in either normoxia (N, n = 10), hypoxia (H, n = 10), hypoxia with melatonin (HM, n = 10), or normoxia with
melatonin (NM, n = 10). Representative cross-section of the aorta of day 19 chick embryos incubated in normoxia (E), hypoxia (F),
hypoxia with melatonin (G), and normoxia with melatonin (H). Scale bar: 200 lm. Significant (P < 0.05) differences are as follows: * ver-
sus N. (one- or two-way ANOVA with Tukey and Bonferroni post hoc test, respectively).
Fig. 8. Peripheral vasodilator function in normoxic or hypoxic chick embryos with or without melatonin treatment at day 19 of incuba-
tion. Values are mean  S.E.M. for relaxant responses to sodium nitroprusside (SNP, A) and to acetylcholine (ACh, B), and vasodilata-
tion to ACh expressed as area under the curve before and after LNAME treatment (AUC, C) for femoral arterial segments isolated from
chick embryos incubated in either normoxia (N, n = 10), hypoxia (H, n = 10), hypoxia with melatonin (HM, n = 10), or normoxia with
melatonin (NM, n = 10). For (C), the AUC is presented for ACh-induced relaxation (complete bar with positive S.E.M.), for ACh-
induced relaxation following treatment with L-NAME (NO-independent component, gray bar with negative S.E.M.), and for the remain-
ing AUC after ACh with L-NAME (NO-dependent component, black bar with negative S.E.M.). Significant (P < 0.05) differences are as
follows: * versus N. † H versus HM for pD2 (B) and AUC (C) (one- or two-way ANOVA with Tukey and Bonferroni post hoc test,
respectively).
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VEGF, during hypoxic development protected cardiomy-
ocyte contractility and prevented ventricular dilatation.
Data in the present study support that VEGF is an
involved mechanism triggering dilated cardiomyopathy in
the hypoxic chick embryo, as melatonin treatment of the
chronically hypoxic chick embryo normalized cardiac
VEGF expression. Melatonin may restore the appropriate
level of VEGF in the fetal heart by destabilizing the
hypoxia-induced HIF-1a activity on the transcription of
vegf, as reported in cancer cells [45].
It is of interest that the direct protective actions of mela-
tonin on the developing cardiovascular system of the
hypoxic chick embryo occurred at doses lower than those
used to avoid jet lag in humans and achieving circulating
concentrations similar to those measured in other studies
[13, 14, 46]. In control embryos, circulating melatonin
levels peaked within 30 min of administration, and detect-
able levels of melatonin were still present 8 hr after treat-
ment. It is known that genomic antioxidant actions of
melatonin remain long after peak concentrations have
been achieved [39, 47]. In addition, the breakdown prod-
ucts of melatonin also have direct antioxidant actions [48].
Combined, these findings suggest that daily treatment in
the present study provided sufficient antioxidant cover.
Interestingly, the profile of the change in melatonin con-
centration following administration between normoxic and
hypoxic chick embryos was different, despite no difference
in the total circulating concentration of melatonin
achieved within the 24-hr day between groups. The reason
for the delay in the increase in melatonin concentrations
following administration in hypoxic chick embryos is not
clear, but it could be due to either a slower uptake of
melatonin from the chorioallantoic vessels and/or faster
metabolism and breakdown of melatonin in the normoxic
embryo. A previous study in rats [49] supports both
options as compared to normoxic controls, there was also
a lag in the appearance of the peak plasma concentration
and in the subsequent clearance of acetaaminophen in
hypoxic rats following oral administration.
One final consideration is that a very recent study from
our laboratory has reported that melatonin treatment in
late gestation fetal sheep may weaken the fetal brain spar-
ing circulatory response to an acute hypoxic episode as
may occur intrapartum during normal labor [50]. How-
ever, in that study only the effects of melatonin on periph-
eral rather than cerebral blood flow in the fetus were
determined. Clearly, the beneficial effects of melatonin in
protecting the developing fetal cardiovascular system in
pregnancy complicated by chronic fetal hypoxia have to
be balanced against the possible effects of melatonin
adversely affecting the fetal brain sparing defence to intra-
partum hypoxia. Therefore, there is an urgent need to
establish the effects of melatonin on cerebral perfusion in
the fetus exposed to acute or to chronic hypoxia, prior to
translation to the human clinical situation.
In conclusion, melatonin has direct protective effects on
the fetal heart and circulation in addition to beneficial
effects on placental function in development complicated
by chronic fetal hypoxia. We also provide the first evi-
dence to support that melatonin can rescue cardiac dys-
function triggered by developmental hypoxia despite
antioxidant treatment starting much later than the onset
of hypoxia. Therefore, melatonin may be an attractive
antioxidant candidate for translation to human therapy as
it is not only able to be administered in tolerable doses but
it also rescues fetal cardiovascular dysfunction long after
the onset of chronic fetal hypoxia, thereby permitting
antioxidant treatment following FGR diagnosis. Neverthe-
less, future research will have to balance these strong
protective effects of melatonin on the developing cardio-
vascular system during chronic hypoxia against possible
adverse effects of antioxidants on the fetal cardiovascular
defence to acute hypoxia.
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